Kayentis Partners With OmniComm to Offer Integrated EDC and eCOA Solutions
Fort Lauderdale, FL, June 6, 2018 - OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology, today announced a partnership with Kayentis, a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for patient data collection in clinical trials. Under the terms of the partnership, the two companies will work together to provide life science clients with OmniComm’s TrialMaster® electronic data capture (EDC) suite integrated with Clin’form®, eCOA solution Suite from Kayentis - thereby offering an enhanced integration of the two platforms.
Prior to the partnership, a number of clients had independently selected both OmniComm and Kayentis for best-in-class data capture solutions. Therefore, the strategic relationship represents a logical fit and brings an exciting opportunity to streamline EDC and eCOA data capture, according to executives from both companies.
“After successfully implementing projects alongside OmniComm, we are thrilled to grow our partnership and bring it to this new step. Both companies share strong values and strive to provide customers, clinical sites and patients with the most efficient, easy-to-use and comprehensive solutions,” said Guillaume Juge, CEO at Kayentis.
Smart phones, tablets and other devices serve an expanding role in clinical trials as doctors, nurses and other researchers increasingly use mobile devices to collect trial data. Likewise, patients using mobile devices and wearable technology have heightened the need for electronic patient-reported outcome (ePRO) solutions.
Through joint marketing and business development initiatives, the two companies will work together to deliver OmniComm’s EDC technology and services integrated with eCOA solutions from Kayentis.
“OmniComm is delighted to be forging a formal relationship with Kayentis that will benefit our clients who need eCOA technology,” said Stephen Johnson, president & CEO of OmniComm Systems. “More and more, we see the voice of the patient/subject becoming critical to the success of studies, and we feel that Kayentis’ technology and support will bring enormous value.”
About Kayentis
Kayentis is a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for patient data collection in clinical trials. Created in 2003, Kayentis has specialized in eCOA solutions since 2009, developing a full range of services and extending its solutions portfolio to support pharmaceutical companies, biotechnology companies and CROs. Today, with experience of more than 150 clinical trials in 75+ countries (6,500 sites and 50,000 patients) and in a broad range of therapeutic areas, Kayentis adds value to data quality and clinical trial efficiency with innovative and intuitive solutions. Please visit kayentis.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Clin’form is a registered trademark of Kayentis.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
Guillaume Juge Kayentis
+33476005420
Gjuge@kayentis.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
